Revance Therapeutics Inc (NASDAQ:RVNC) has received an average recommendation of “Buy” from the eleven ratings firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $45.00.

RVNC has been the subject of a number of research analyst reports. JMP Securities initiated coverage on shares of Revance Therapeutics in a report on Tuesday, August 22nd. They issued an “outperform” rating and a $34.00 price target for the company. Zacks Investment Research raised shares of Revance Therapeutics from a “hold” rating to a “buy” rating and set a $26.00 price objective for the company in a research note on Tuesday, August 22nd. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $50.00 price objective on shares of Revance Therapeutics in a research note on Wednesday, September 6th.

Shares of Revance Therapeutics (RVNC) traded up $1.70 during midday trading on Friday, reaching $35.40. 858,200 shares of the company’s stock were exchanged, compared to its average volume of 255,618. Revance Therapeutics has a 52 week low of $18.00 and a 52 week high of $37.20.

Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.95) by ($0.06). Revance Therapeutics had a negative net margin of 37,161.00% and a negative return on equity of 67.85%. The business had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.05 million. During the same period in the previous year, the company posted ($0.64) earnings per share. Revance Therapeutics’s revenue was up .0% compared to the same quarter last year. equities research analysts anticipate that Revance Therapeutics will post -3.73 earnings per share for the current fiscal year.

In other news, CFO Lauren P. Silvernail sold 10,000 shares of the company’s stock in a transaction dated Tuesday, November 7th. The stock was sold at an average price of $26.83, for a total value of $268,300.00. Following the transaction, the chief financial officer now owns 59,006 shares in the company, valued at approximately $1,583,130.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mark J. Foley bought 20,000 shares of the company’s stock in a transaction dated Tuesday, November 7th. The stock was acquired at an average price of $26.96 per share, for a total transaction of $539,200.00. Following the acquisition, the director now directly owns 6,000 shares in the company, valued at $161,760. The disclosure for this purchase can be found here. Insiders have sold 36,426 shares of company stock valued at $956,026 over the last ninety days. Insiders own 18.86% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. increased its holdings in shares of Revance Therapeutics by 4.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,626,603 shares of the biopharmaceutical company’s stock valued at $95,743,000 after purchasing an additional 166,759 shares during the period. Franklin Resources Inc. increased its holdings in shares of Revance Therapeutics by 13.1% in the 2nd quarter. Franklin Resources Inc. now owns 3,375,238 shares of the biopharmaceutical company’s stock valued at $89,106,000 after purchasing an additional 391,638 shares during the period. Bank of New York Mellon Corp increased its holdings in shares of Revance Therapeutics by 14.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 2,079,562 shares of the biopharmaceutical company’s stock valued at $54,901,000 after purchasing an additional 261,764 shares during the period. Vanguard Group Inc. increased its holdings in shares of Revance Therapeutics by 7.3% in the 2nd quarter. Vanguard Group Inc. now owns 931,623 shares of the biopharmaceutical company’s stock valued at $24,595,000 after purchasing an additional 63,505 shares during the period. Finally, State Street Corp increased its holdings in shares of Revance Therapeutics by 0.6% in the 2nd quarter. State Street Corp now owns 452,490 shares of the biopharmaceutical company’s stock valued at $11,944,000 after purchasing an additional 2,637 shares during the period. Institutional investors own 76.69% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Revance Therapeutics Inc (RVNC) Receives $43.88 Consensus Target Price from Brokerages” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.watchlistnews.com/revance-therapeutics-inc-rvnc-receives-43-88-consensus-target-price-from-brokerages/1774956.html.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.